Zavik Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 13 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
About Zavik Drugs
Zavik Drugs Private Limited (ZDPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 December 2011 and has a history of 13 years and one month. Its registered office is in Chandigarh, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Suresh Kumar and Ankit Mittal serve as directors at the Company.
Company Details
-
Location
Chandigarh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232CH2011PTC033451
-
Company No.
033451
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
30 Dec 2011
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
What products or services does Zavik Drugs Private Limited offer?
Zavik Drugs Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Common Disease Medicines, Antihistamines, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Herbal Cough Syrup, Vitamin & Multivitamin Injections, Antibiotic Injection, Pain Relief Drugs & Pharmaceuticals.
Who are the key members and board of directors at Zavik Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suresh Kumar
|
Director | 30-Dec-2011 | Current |
|
Ankit Mittal
|
Director | 30-Dec-2011 | Current |
Financial Performance of Zavik Drugs.
Zavik Drugs Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zavik Drugs?
In 2017, Zavik Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Eviza Biotech Private LimitedSuresh Kumar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zavik Drugs?
Unlock and access historical data on people associated with Zavik Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zavik Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zavik Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
